Literature DB >> 15702040

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.

Matthew D Snape1, Dominic F Kelly, Ben Green, E Richard Moxon, Ray Borrow, Andrew J Pollard.   

Abstract

BACKGROUND: There is an increased risk of invasive meningococcal disease during the teenage years. A cohort of children vaccinated with a single dose of meningococcal C protein-polysaccharide conjugate (MenC) vaccine in early childhood during the U.K. catch up campaign will enter this age group during the coming decade. The duration of protective immunity against invasive meningococcal C disease provided by this single dose regimen is uncertain.A serum bactericidal titer of <1/8 correlates with susceptibility to invasive meningococcal disease. We assessed this correlate of protection in a cohort of children approximately 2 years after a single dose of vaccine.
METHODS: Serum bactericidal activity was assessed in 94 children (median age, 4.0 years) at a median time of 1.8 years after vaccination.
RESULTS: Of the 94 children, 59 (63%) had a serum bactericidal titer <1/8.
CONCLUSION: The data from this study add to previous evidence indicating that immunity wanes rapidly after vaccination with serogroup C meningococcal glycoconjugate vaccines in infancy and early childhood. Such observations suggest that booster doses of MenC vaccine may be needed to maintain the successful contribution this vaccine has made to child health in the United Kingdom.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15702040     DOI: 10.1097/01.inf.0000151029.58752.27

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  26 in total

Review 1.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Authors:  Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

3.  Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?

Authors:  Theodore F Tsai; Ray Borrow; Hanspeter E Gnehm; Bernard Vaudaux; Ulrich Heininger; Daniel Desgrandchamps; Christoph Aebi; Paul Balmer; Ronald D Pedersen; Bernard Fritzell; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.

Authors:  A Khatami; A Peters; H Robinson; N Williams; A Thompson; H Findlow; A J Pollard; M D Snape
Journal:  Clin Vaccine Immunol       Date:  2011-10-28

5.  UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  This Statement Was Prepared By Dr B Warshawsky
Journal:  Can Commun Dis Rep       Date:  2013-01-02

6.  Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.

Authors:  Ray Borrow; Nick Andrews; Helen Findlow; Pauline Waight; Joanna Southern; Annette Crowley-Luke; Lorraine Stapley; Anna England; Jamie Findlow; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

7.  Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.

Authors:  Heinz-J Schmitt; Gudrun Maechler; Pirmin Habermehl; Markus Knuf; Roland Saenger; Norman Begg; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

8.  Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?

Authors:  Richarda M de Voer; Fiona R M van der Klis; Laetitia E M Niers; Ger T Rijkers; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

Review 9.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

Review 10.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.